Spots Global Cancer Trial Database for mibg
Every month we try and update this database with for mibg cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma | NCT00992173 | Neuroblastoma | Ultratrace Iobe... | 12 Months - | Molecular Insight Pharmaceuticals, Inc. | |
| I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma | NCT00590096 | Neuroblastoma Pheochromocytom... | 2 Weeks - | Children's Hospital Medical Center, Cincinnati | ||
| Combination Chemotherapy Followed by Stem Cell Transplant in High-risk Neuroblastoma Patients | NCT03042429 | Neuroblastoma | Cycles N8, N5 a... Cycles N5 and N... | 6 Months - 21 Years | University of Cologne | |
| MIBG Therapy for Patients With MIBG Avid Tumors | NCT02378428 | MIBG Avid Tumor... | MIBG | 12 Months - 65 Years | Nationwide Children's Hospital | |
| Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma | NCT02961491 | Pheochromocytom... Paraganglioma | Ultratrace Iobe... | 12 Years - | Molecular Insight Pharmaceuticals, Inc. | |
| Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors | NCT03044977 | Neuroendocrine ... Neuroendocrine ... | 90Y-DOTA-3-Tyr-... 131I-MIBG | 18 Years - 80 Years | University of Iowa | |
| A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma | NCT03015844 | Neuroblastoma Pheochromocytom... | 131-I-meta-iodo... | 365 Days - 29 Years | Northwell Health | |
| A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma | NCT03015844 | Neuroblastoma Pheochromocytom... | 131-I-meta-iodo... | 365 Days - 29 Years | Northwell Health | |
| 131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol | NCT01370330 | Neuroblastoma | Metaiodobenzylg... | 1 Year - | University of California, San Francisco | |
| ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid | NCT00339131 | Pheochromocytom... Paraganglioma Carcinoid | Ultratrace iobe... | 18 Years - | Molecular Insight Pharmaceuticals, Inc. | |
| Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction | NCT03165292 | Very High Risk ... | mIBG Topotecan Thiotepa Autologous stem... | - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma | NCT00458952 | Pheochromocytom... Paraganglioma | Ultratrace Iobe... | 18 Years - | Molecular Insight Pharmaceuticals, Inc. | |
| High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma | NCT01313936 | Neuroblastoma | Metaiodobenzylg... | 1 Year - 30 Years | University of California, San Francisco | |
| High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma | NCT01313936 | Neuroblastoma | Metaiodobenzylg... | 1 Year - 30 Years | University of California, San Francisco | |
| A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors | NCT01413503 | Pheochromocytom... Paraganglioma | 131I-MIBG | 4 Years - | University of California, San Francisco | |
| I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma | NCT00590096 | Neuroblastoma Pheochromocytom... | 2 Weeks - | Children's Hospital Medical Center, Cincinnati | ||
| A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors | NCT01413503 | Pheochromocytom... Paraganglioma | 131I-MIBG | 4 Years - | University of California, San Francisco | |
| Combination Chemotherapy Followed by Stem Cell Transplant in High-risk Neuroblastoma Patients | NCT03042429 | Neuroblastoma | Cycles N8, N5 a... Cycles N5 and N... | 6 Months - 21 Years | University of Cologne |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
